Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
NCT ID: NCT00391846
Last Updated: 2012-06-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
252 participants
INTERVENTIONAL
2006-10-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of Drug Levels for Pharmacotherapy of Heart Failure
NCT06035978
Cardiac Hormone Replacement With Brain Natriuretic Peptide (BNP) in Heart Failure
NCT00252187
Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure
NCT04107220
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
NCT02874794
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
NCT03988634
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Guided by NT-proBNP
Treatment guided by clinical symptoms and signs + NTproBNP
Captopril
Enalapril
Lisinopril
Ramipril
Trandolapril
Bisoprolol
Carvedilol
Metoprolol succinate
Candesartan
Valsartan
Eplerenone
Spironolactone
Diuretics
HF treatment according to Swedish guidelines
Blood samples
The Kansas City Cardiomyopathy Questionnaire (KCCQ)
Not Guided by NT-proBNP
Treatment guided by clinical symptoms and signs
Captopril
Enalapril
Lisinopril
Ramipril
Trandolapril
Bisoprolol
Carvedilol
Metoprolol succinate
Candesartan
Valsartan
Eplerenone
Spironolactone
Diuretics
HF treatment according to Swedish guidelines
Blood samples
The Kansas City Cardiomyopathy Questionnaire (KCCQ)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Captopril
Enalapril
Lisinopril
Ramipril
Trandolapril
Bisoprolol
Carvedilol
Metoprolol succinate
Candesartan
Valsartan
Eplerenone
Spironolactone
Diuretics
HF treatment according to Swedish guidelines
Blood samples
The Kansas City Cardiomyopathy Questionnaire (KCCQ)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* New York Heart Association(NYHA) class II-IV,
* NTproBNP males\>800 ng/L, females \>1000 ng/L
Exclusion Criteria
* Mitral/aortic stenosis,
* Patients already receiving optimal HF treatment,
* Severe reduction of kidney function
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Sweden Medical Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Hans Persson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Danderyd Hospital, Sweden
Bjorn Eriksson, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Alvesta, , Sweden
Research Site
Arvika, , Sweden
Research Site
Bjuv, , Sweden
Research Site
Borensberg, , Sweden
Research Site
Bromma, , Sweden
Research Site
Dalby, , Sweden
Research Site
Eskilstuna, , Sweden
Research Site
Gagnef, , Sweden
Research Site
Gothenburg, , Sweden
Research Site
Hisings Kärra, , Sweden
Research Site
Huddinge, , Sweden
Research Site
Huskvarna, , Sweden
Research Site
Jönköping, , Sweden
Research Site
Kalmar, , Sweden
Research Site
Kungälv, , Sweden
Research Site
Lerum, , Sweden
Research Site
Lessebo, , Sweden
Research Site
Lidköping, , Sweden
Research Site
Lilla Edet, , Sweden
Research Site
Linköping, , Sweden
Research Site
Ludvika, , Sweden
Research Site
Lyckeby, , Sweden
Research Site
Malmo, , Sweden
Research Site
Moheda, , Sweden
Research Site
Motala, , Sweden
Research Site
Örebro, , Sweden
Research Site
Östersund, , Sweden
Research Site
Skanör, , Sweden
Research Site
Söderåkra, , Sweden
Research Site
Stenungsund, , Sweden
Research Site
Stocksund, , Sweden
Research Site
Timrå, , Sweden
Research Site
Uddevalla, , Sweden
Research Site
Ulricehamn, , Sweden
Research Site
Umeå, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Vaxjo, , Sweden
Research Site
Västerås, , Sweden
Research Site
Västervik, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT No. 2006-001259-36
Identifier Type: -
Identifier Source: secondary_id
SIGNAL HF
Identifier Type: -
Identifier Source: secondary_id
D2452L00010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.